Fortune Invites GATC Health’s President, Dr. Rahul Gupta, to CEO Roundtable

The event focused on impact of AI and other disruptive technologies on businesses and bottom lines.

GATC Health is proud to announce its participation in the Fortune CEO Virtual Roundtable, held on November 11, 2025. Hosted and moderated by Fortune Editorial Director Andrew Nusca with Deloitte U.S. CEO Jason Girzadas, the event convened an exclusive group of CEOs and company presidents, including Dr. Rahul Gupta, President of GATC Health, for a dynamic, peer-level dialogue on the most pressing challenges shaping today's business landscape. The event also featured guest speaker Dennis Lockhart, Former President and CEO of the Federal Reserve Bank of Atlanta, with topics ranging from trade policies to the regulatory climate, with an emphasis on AI’s impact on business. 

“I’d like to thank Fortune for extending the invitation to participate in this timely roundtable,” remarked Dr. Gupta. ‘It is both an honor and a privilege to join such an accomplished group of industry leaders whose expertise and insights are truly shaping the future of business. AI is turning challenges into opportunities, as evidenced by our groundbreaking Derisq™ AI report. Derisq delivers highly accurate predictions of safety, efficacy, and potential off-target effects for drug candidates, helping teams confidently de-risk decisions at any stage of development.”

Fortune magazine stands as one of the world’s most respected business publications, renowned for its authoritative rankings such as the Fortune 500 and Most Admired Companies lists. Its roundtables and forums are celebrated as premier gatherings for catalyzing strategic conversation and fostering high-impact connections among global business leaders. As an invite-only event, this forum exemplifies Fortune’s commitment to thought leadership at the highest level, offering a rare opportunity for CEOs to exchange insights, best practices, and strategic solutions with their peers.

About GATC Health

GATC Health is a tech-bio company revolutionizing drug discovery and development by simulating complex human biology to predict how drugs will perform in the body, achieving 91% specificity and 86% sensitivity. Trusted by the world’s largest insurance marketplace, biopharma, researchers, and investment partners, GATC Health’s risk prediction product, the Derisq™ AI report, accurately assesses and predicts drug candidate safety, efficacy, and non-obvious side effects prior to the commitment of development capital. GATC Health’s AI platform is also generative, creating intellectual property, extending pipelines, and optimizing assets. By uniting advanced AI, multiomics, and predictive modeling, GATC Health accelerates breakthroughs and reduces costly late-stage failures to bring safer, more effective therapies to patients worldwide. For more information, visit www.gatchealth.com.